Bank of New York Mellon Corp Acquires New Shares in Avalyn Pharma Inc. $AVLN

Key Points

• Bank of New York Mellon acquired 40,140 Avalyn Pharma shares worth approximately $1.32 million, representing about 0.09% of the company.
• Analyst sentiment is mixed, with ratings ranging from Sell to Strong Buy. The stock carries a consensus “Moderate Buy” rating and an average price target of $60, versus a recent price of $35.88.
• Avalyn reported a quarterly loss of $0.98 per share, beating estimates of $1.03, while analysts expect a full-year loss of $3.81 per share.

Bank of New York Mellon Corp bought a new stake in Avalyn Pharma Inc. (NASDAQ:AVLN - Free Report) in the 2nd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm bought 40,140 shares of the company's stock, valued at approximately $1,321,000. Bank of New York Mellon Corp owned about 0.09% of Avalyn Pharma at the end of the most recent quarter.

Analyst Ratings Changes

AVLN has been the topic of several recent research reports. Weiss Ratings assumed coverage on shares of Avalyn Pharma in a research report on Thursday, August 13th. They set a "sell (d+)" rating on the stock. Wall Street Zen lowered shares of Avalyn Pharma from a "hold" rating to a "sell" rating in a report on Saturday, August 15th. Zacks Research raised Avalyn Pharma to a "hold" rating in a research report on Wednesday, May 27th. Evercore started coverage on Avalyn Pharma in a research report on Tuesday, May 26th. They issued an "outperform" rating and a $51.00 price target on the stock. Finally, Guggenheim initiated coverage on Avalyn Pharma in a research report on Monday, May 25th. They set a "buy" rating and a $80.00 price objective for the company. Two analysts have rated the stock with a Strong Buy rating, two have given a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat, the stock currently has an average rating of "Moderate Buy" and an average price target of $60.00.

Avalyn Pharma Stock Performance

Shares of Avalyn Pharma stock opened at $35.88 on Thursday. The company has a quick ratio of 33.12, a current ratio of 33.12 and a debt-to-equity ratio of 0.04. The firm has a 50 day moving average price of $32.61. Avalyn Pharma Inc. has a 52 week low of $24.15 and a 52 week high of $40.17. The firm has a market capitalization of $1.59 billion and a PE ratio of -1.57.

Avalyn Pharma (NASDAQ:AVLN - Get Free Report) last announced its quarterly earnings results on Wednesday, August 12th. The company reported ($0.98) earnings per share for the quarter, beating the consensus estimate of ($1.03) by $0.05. Research analysts forecast that Avalyn Pharma Inc. will post -3.81 EPS for the current year.

About Avalyn Pharma

We are a clinical-stage biopharmaceutical company pioneering inhaled therapies to transform the treatment paradigm of serious, rare respiratory diseases with significant unmet needs. Our approach is designed to address the limitations of current oral therapies by delivering optimized inhaled formulations of approved oral medicines directly to the lungs to enhance efficacy and minimize systemic exposure that contributes to side effects and treatment discontinuation. Our current pipeline is focused on treating pulmonary fibrosis, a life-threatening disease with a median survival of three to five years, which is a significantly shorter prognosis than that observed for many forms of cancer.

Want to see what other hedge funds are holding AVLN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Avalyn Pharma Inc. (NASDAQ:AVLN - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.